摘要
ALL是儿童最常见的恶性肿瘤,应用目前的联合化疗方法,5a生存率超过80%。骨骼并发症可发生于ALL诊断时、治疗过程中和治疗结束后,影响ALL的治疗和生存。骨坏死(ON)是儿童ALL治疗过程中最严重的并发症之一,可影响高达1/3的接受治疗的儿童。ON的危险因素包括糖皮质激素的使用、诊断时年龄及放疗等。双膦酸盐治疗可减轻患者疼痛,减少止痛药用量及改善骨关节功能。间充质干细胞可提高手术治疗的疗效。
With current treatment regimens,children with acute lymphoblastic leukemia（ALL） can expect a better than 80% chance of 5-year survival,with the majority surviving into adulthood.Skeletal morbidity is increasingly being recognized in these individuals and may occur at diagnosis,during and following treatment.Osteonecrosis（ON） has been recognized as an important complication of treatment for ALL and can affect up to one third of patients treated for ALL.The risk factors for ON include glucocorticoid therapy,radiation,and adolescent age at ALL diagnosis.Bisphosphonate can improve pain scores,analgesic requirement and musculoskeletal function.Human multipotent mesenchymal stromal cells displayed biological properties that may add to the efficency of surgical treatment in ON.
出处
《实用儿科临床杂志》
CAS
CSCD
北大核心
2011年第3期212-216,共5页
Journal of Applied Clinical Pediatrics
